FierceBiotech2d
Boehringer's phase 3 schizophrenia program misses primary goal
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...
GlobalData on MSN1d
Boehringer Ingelheim announces Phase III schizophrenia failures
The company said that all of its CONNEX trials failed to meet expectations showing no impact on patients living with ...
Pharmabiz1d
Boehringer Ingelheim’s phase III CONNEX clinical programme of iclepertin in schizophrenia fails to meet primary and key secondary endpoints
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
Monthly Prescribing Reference1d
Iclepertin Fails to Improve Cognitive Impairment in Schizophrenia Trial
The CONNEX program consisted of the randomized, double-blind, placebo-controlled phase 3 CONNEX-1, CONNEX-2, and CONNEX-3 studies ...
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
Boehringer Ingelheim and Synaffix B.V. ("Synaffix"), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug ...
Boehringer Ingelheim Acquires Fourth License for the Development of Novel Antibody Based Cancer Treatments from Oxford BioTherapeutics
Oxford, UK and San Jose, California, 9 January 2024 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a ...
Sutro Biopharma and Boehringer Ingelheim BioXcellenceâ„¢ collaboration: Established first-in-class cell-free capabilities at commercial scale
Boehringer Ingelheim BioXcellence™ and Sutro Biopharma Inc.today announced that they successfully applied Sutro’ ...
Boehringer Ingelheim Limited: Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with schizophrenia, showing primary and key secondary endpoints were ...